IMMUNOTHERAPY

This study compares a new treatment approach for high-risk rectal cancer: short-course radiation followed by immunotherapy (toripalimab) and chemotherapy (FOLFOX) versus the standard long-course chemoradiation. The goal is to see if the new approach leads to more complete tumor r…

This study tests a new drug called Ivonescimab for people with non-small cell lung cancer who need surgery. The drug is given before surgery to shrink tumors and make them easier to remove. The study compares Ivonescimab to standard treatments and looks at how well it works and w…

This early-phase study tests whether spending time in a cool room (around 18°C for 12 hours a day) can make standard immunotherapy drugs work better for people with solid tumors. Twenty-four adults with various solid cancers will receive cold exposure alongside their usual PD-1/P…

This study tests whether a urine DNA test can help guide when to stop immunotherapy in people with a very high-risk type of bladder cancer that cannot be fully removed by surgery. About 53 participants will receive immunotherapy and then be monitored with urine tests and scans. I…

This phase 3 trial tests whether adding an immunotherapy drug (HLX10) to standard chemotherapy and radiation before surgery improves outcomes for people with locally advanced rectal cancer. It compares short-course versus long-course radiation, both followed by immunotherapy and …

This study tests a new treatment plan for people with advanced liver cancer that has spread to blood vessels or a few other spots. The plan combines chemotherapy directly into the liver, two immunotherapy drugs, a targeted therapy, and precise radiation. The goal is to see if thi…

This study tests whether adding radiotherapy to a drug combination (fruquintinib and sintilimab) can help control colorectal cancer that has spread to the liver and hasn't responded to two prior treatments. About 62 adults with a specific type of colorectal cancer (MSS/pMMR) will…

This phase 2 trial is testing whether adding a dietary supplement called β-hydroxybutyrate to a standard treatment plan (short-course radiotherapy, immunotherapy, and chemotherapy) can improve outcomes for people with locally advanced rectal cancer. The study will enroll 25 adult…

This study tests whether adding immunotherapy (a drug that helps the immune system fight cancer) after standard chemotherapy and radiation can help people with advanced esophageal cancer live longer without the disease getting worse. About 452 adults with a specific type of esoph…

This study tests whether adding an oral probiotic (Biolosion) to standard chemotherapy before surgery can help eliminate more cancer cells in women with early-stage triple-negative breast cancer. About 192 participants will receive either standard treatment alone or standard trea…

This study tests a sequence of two immunotherapy drugs, blinatumomab and inotuzumab ozogamicin, in people with B-cell acute lymphoblastic leukemia (B-ALL). It includes newly diagnosed patients who are older or too frail for intensive chemotherapy, as well as those whose cancer ha…

This phase 2 trial tests whether adding the drug narlumosbart and precise radiation therapy to standard first-line treatment can help people with advanced non-small cell lung cancer that has spread to the bones. The study will enroll 27 adults who have not had prior systemic ther…

This phase 2 trial is testing whether adding a probiotic called Probio-M9 to standard chemoradiation and an immunotherapy drug (tislelizumab) can improve outcomes for people with locally advanced rectal cancer. About 50 participants will be randomly assigned to receive either the…

This large phase 3 study is testing different combinations of chemotherapy, radiation, immunotherapy, and targeted drugs given before surgery for esophageal cancer. The goal is to find which approach works best to improve survival. The trial will enroll 2,000 adults with stage I …

This study is looking at the best way to treat esophageal cancer that cannot be removed by surgery. It will follow 2,000 patients who receive chemoradiotherapy (radiation plus chemotherapy) along with possible immunotherapy or targeted drugs. The goal is to see which combinations…

This study tests whether adding immunotherapy to a precise type of radiotherapy (sparing tumor-draining lymph nodes) and chemotherapy can help adults with advanced esophageal cancer live longer without the disease getting worse. About 432 participants will receive either the comb…

This phase 2 trial is testing whether a combination of two chemotherapy drugs (paclitaxel or nab-paclitaxel), an immunotherapy (pembrolizumab), and a bladder drug (mirabegron) can shrink tumors in people with ovarian cancer that has come back after initial treatment. About 20 adu…

This study tests a combination of four drugs (iparomlimab, tuvonralimab, apatinib, and irinotecan) in 39 adults with advanced AFP-producing stomach or gastroesophageal junction cancer that has worsened after initial immunotherapy and chemotherapy. The goal is to see if this new m…

This early-stage trial is testing a new drug called VSV-02 in 6 people with advanced solid tumors (like melanoma, breast, or lung cancer) who have no good treatment options left. VSV-02 is a modified virus that is injected into a vein and directly into the tumor, aiming to kill c…

This study tests a new approach for people with advanced gastroesophageal junction cancer that cannot be removed with surgery right away. The treatment combines targeted radiation, immunotherapy, and chemotherapy to shrink the tumor enough for surgery. The goal is to see if this …

This study is testing a new drug called ABT-301 combined with two other drugs (tislelizumab and bevacizumab) in people with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if the combination is safe and can shrink tumors. Abo…

This study tests whether a special low-calorie, plant-based diet that mimics fasting can help patients with stage IV non-small cell lung cancer respond better to maintenance immunotherapy. Sixty-six participants will follow the diet for three cycles while continuing their regular…

This study tests a new treatment called RAK cell therapy, made from human umbilical cord blood, for people with advanced stomach cancer that has spread or come back after standard treatment. The goal is to see if it can help patients live longer and keep the cancer from growing, …

This study is for people with locally advanced rectal cancer that hasn't spread. It tests whether adding an immunotherapy drug (PD-1 inhibitor) to a standard treatment plan (short-course radiation plus chemotherapy and targeted therapy) can lead to a complete disappearance of the…

This phase 2 trial tests whether adding radiotherapy and two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemotherapy can improve outcomes for people with resectable stomach or gastroesophageal junction cancer. About 40 participants will be randomly assigned to…

This study tests whether taking oral sorbitol, a common sugar alcohol, can enhance the effects of standard chemotherapy and an immunotherapy drug (tirellizumab) in people with locally advanced stomach cancer. Eighty participants will receive either sorbitol or a placebo alongside…

This trial tests whether giving the immunotherapy drug camrelizumab before surgery can help completely remove T4 colon cancers that have a specific genetic feature (dMMR). These cancers often don't respond well to standard chemotherapy. The study will enroll 18 adults who will re…

This study tests whether Reiki, a gentle hands-on relaxation therapy, can help adults with cancer who feel very tired from immunotherapy. Twelve participants will either receive six weekly Reiki sessions right away or after a waiting period. Researchers will measure changes in fa…

This study is collecting live tumor samples from 2,000 cancer patients undergoing standard biopsies. Researchers will analyze these samples to understand how tumors respond to immunotherapy drugs outside the body. The goal is to develop a method to predict which patients will res…

This study looks back at 600 advanced lung cancer patients who received immunotherapy. Researchers will analyze their tissue samples and genetic data to find patterns linked to long-term survival. They aim to build an AI model that can predict survival from standard microscope im…

This study is testing whether a 12-week home-based walking program can change the immune system in people with lung cancer. Fifty patients will either do moderate continuous walking, high-intensity interval walking, or receive standard exercise advice. Researchers will measure ch…

This study is gathering detailed information from 500 people with small cell lung cancer to learn how to tailor treatments like radiation and immunotherapy to each patient. The goal is to find the best timing and doses of radiotherapy to work with immunotherapy, improving outcome…

This study follows 200 adults with advanced cancer who are receiving immunotherapy. Researchers will track their physical and emotional distress, financial burden, care needs, and quality of life over one year. The goal is to develop a tool that can predict which patients are at …

This study watches how immunotherapy for advanced cancer changes patients' physical fitness and quality of life. About 67 adults will do fitness tests and fill out questionnaires before starting treatment and again 12 weeks later. Researchers will also track long-term outcomes li…

This study looks at how well venom immunotherapy protects people with Jack Jumper ant allergy years after treatment stops. About 100 adults who completed 3-6 years of therapy and have been off treatment for at least 18 months will have a supervised sting challenge and blood test.…

This study looks at whether advanced blood tests and artificial intelligence can help detect lung cancer recurrence earlier and without invasive procedures. About 100 adults who had surgery for stage IB-IIIA lung cancer and received standard chemo-immunotherapy before surgery wil…

This study looks at whether a patient's emotional state—like depression or anxiety—affects how well advanced liver cancer treatment works. Researchers will follow 90 people with liver cancer who are getting a combination of chemotherapy, targeted therapy, and immunotherapy. They …

This study is testing whether a simple blood test can predict how well immunotherapy works in people with head and neck cancer. Researchers will measure a protein called PD-L1 on tumor cells that have escaped into the bloodstream. The goal is to see if these 'liquid biopsies' can…

This study is looking at tiny particles in the blood called microRNA and circulating tumor cells in 300 cancer patients who are about to start immunotherapy. By comparing blood samples taken before and after treatment, researchers hope to see how these markers change. The goal is…

This study follows 500 lung cancer patients who received immunotherapy before their main treatment. Researchers want to see whether surgery (removing part or all of a lung) or non-surgery options like radiation lead to better long-term outcomes. The goal is to find the best appro…